Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calculate a total neurological deficit. Together with his co-workers, Fog in 1972 was the first to report the association between MS and the human leukocyte antigen system. Fog can be considered as the father of immunomodulatory therapy in MS, treating MS patients with the first transfer factor, and as early as 1980, he was the first to treat MS with intramuscular natural interferon.
DawsonJW. The histology of disseminated sclerosis. Edinb Med J1916; 17: 229–241.
8.
SteinerG. Krankheitserreger und Gewebsbefund bei progressiver Paralyse Pathogenese des herdförmigen Markscheidenzerfalls. Zeitschrift gesamte Neurologie Psychiatrie1931; 131: 632–673.
9.
PutnamTJ. Studies in multiple sclerosis: IV. ‘Encephalitis’ and sclerotic plaques produced by venular obstruction. Arch Neurol Neurosurg Psychiat1935; 33: 929–940.
10.
Maeder Le RoyMA. Zur Frage der entzündlichen Erscheinungen bei der multiplen Sklerose. Arb Ad Neurol Inst Ad Wien Univ1931; 33: 63–73.
11.
FogT. On the vessel-plaque relationships in the brain in multiple sclerosis. Acta Neurol Scand Suppl1964; 40: SUPPL 10: 9–15.
12.
BramowSFrischerJMLassmannH, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain2010; 133(10): 2983–2998.
13.
FogT. On the mystery of multiple sclerosis. J Neurol Neurosurg Psychiatry1987; 50: 1086.
14.
FogTLinnemannF. The course of multiple sclerosis in 73 cases with computer-designed curves. Acta Neurol Scand Suppl1970; 47: 3–175.
15.
FogT. A scoring system for neurological impairment in multiple sclerosis. Acta Neurol Scand Suppl1965; 13Pt 2: 551–555.
16.
FogT. The course of multiple sclerosis. Acta Neurol Scand1966; 42: 608–611.
17.
LerayEYaouanqJLe PageE, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain2010; 133(Pt 7): 1900–1913.
18.
ConfavreuxCCompstonA. The natural history of multiple sclerosis. In: McAlpine’s (ed.) Multiple sclerosis. 4th ed.London: Elsevier, 2006, pp. 183–269.
19.
GiovannoniGPopescuVWuerfelJ, et al. Smouldering multiple sclerosis: The ‘real MS’. Ther Adv Neurol Disord2022; 15: 17562864211066751.
JersildCSvejgaardAFogT. HL-A antigens and multiple sclerosis. Lancet1972; 1: 1240–1241.
22.
JersildCFogTHansenGS, et al. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet1973; 2: 1221–1225.
23.
International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science2019; 365: eaav7188.
24.
JersildCAmmitzbollTClausenJ, et al. Association between HL-A antigens and measles antibody in multiple sclerosis. Lancet1973; 1: 151–152.
25.
RastogiSCClausenJOffnerH, et al. Partial purification of MS specific brain antigens. Acta Neurol Scand1979; 59(6): 281–296.
26.
OffnerHFogTRastogiSC, et al. The enhancing effect of multiple sclerosis brain homogenates on the active E-rosette forming lymphocytes in neurological disorders. Acta Neurol Scand1979; 59(2–3): 49–54.
27.
JansHHeltbergAZeebergI, et al. Immune complexes and the complement factors C4 and C3 in cerebrospinal fluid and serum from patients with chronic progressive multiple sclerosis. Acta Neurol Scand1984; 69(1): 34–38.
28.
AmmitzbollTGlausenJFogT. Oligoclonal IgG and measles antibody in CSF of multiple sclerosis patients. Acta Neurol Scand1977; 56(2): 153–158.
29.
JariusSEichhornPFranciottaD, et al. The MRZ reaction as a highly specific marker of multiple sclerosis: Re-evaluation and structured review of the literature. J Neurol2017; 264(3): 453–466.
30.
FogT. Some experiences with ACTH-treatment in disseminated sclerosis. Acta Endocrinol (Copenh)1952; 9(3): 213–257.
31.
FogT. The long-term treatment of multiple sclerosis with corticoids. Acta Neurol Scand Suppl1965; 13Pt 2: 473–484.
32.
ZivadinovRRudickRADe MasiR, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology2001; 57: 1239–1247.
33.
SorensenPSMellgrenSISvenningssonA, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): A randomised, placebo-controlled trial. Lancet Neurol2009; 8(6): 519–529.
34.
JersildCPlatzPSvejgaardA, et al. Transfer factor treatment of multiple sclerosis. A pilot study. Acta Neurol Scand Suppl1977; 63: 253–264.
35.
EmodiGJustMGrobP. Letter: Circulating interferon after transfer-factor therapy. Lancet1973; 2: 1382.
36.
FogTPedersenLRaunNE, et al. Long-term transfer-factor treatment for multiple sclerosis. Lancet1978; 1: 851–853.
37.
JacobsLSalazarAMHerndonR, et al. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet1986; 2: 1411–1413.
